A 2014 update on coagulation management for cardiopulmonary bypass

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 18, Issue 2, 2014, Pages 177-189

  Thiele, Robert H ^a   Raphael, Jacob ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

antifibrinolytics; cardiopulmonary bypass; coagulation; coagulopathy; point of care monitoring

Indexed keywords

ADENOSINE DIPHOSPHATE; AMINOCAPROIC ACID; ANTITHROMBIN III; APROTININ; CLOPIDOGREL; D DIMER; DESMOPRESSIN; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOGEN CONCENTRATE; FIBRINOGEN RECEPTOR; FRESH FROZEN PLASMA; LYSINE DERIVATIVE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; PRASUGREL; PROSTACYCLIN; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR; RECOMBINANT PROTEIN; THROMBOMODULIN; THROMBOPLASTIN; THROMBOXANE A2; TICAGRELOR; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLASSIFICATION ALGORITHM; CLINICAL TRIAL (TOPIC); CRITICALLY ILL PATIENT; CRYOPRECIPITATE; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEART SURGERY; HEMOSTASIS; HOSPITALIZATION; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PLASMA; POINT OF CARE TESTING; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROTATIONAL THROMBOELASTOMETRY; THROMBOCYTE; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; TRANSFUSION RELATED ACUTE LUNG INJURY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD COAGULATION DISORDERS; POINT OF CARE SYSTEM;

BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; FACTOR VIIA; FIBRINOGEN; HUMANS; POINT-OF-CARE SYSTEMS; VITAMIN K;

EID: 84901778003     PISSN: 10892532     EISSN: 19405596     Source Type: Journal    
DOI: 10.1177/1089253214534782     Document Type: Review

References (140)

1. Dyke C, Aronson S, Dietrich W, et al. Universal definition of perioperative bleeding in adult cardiac surgery [published online December 9, 2013]. J Thorac Cardiovasc Surg. :
2. Görlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA. Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth. 2013 ; 27: S20 - S34
3. Despotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion. 2008 ; 48: 2S - 30S
4. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996 ; 111: 1037-1046
5. Tanaka KA, Bader SO, Görlinger K. Novel approaches in management of perioperative coagulopathy. Curr Opin Anaesthesiol. 2014 ; 27: 72-80
6. Ranucci M, Baryshnikova E, Castelvecchio S, Pelissero G. Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. Ann Thorac Surg. 2013 ; 96: 478-485
7. Christensen MC, Krapf S, Kempel A, von Heymann C. Costs of excessive postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg. 2009 ; 138: 687-693
8. Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion. 2004 ; 44: 1453-1462
9. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008 ; 358: 1229-1239
10. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J of Anaesthesiol. 2013 ; 30: 270-382
11. Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011 ; 91: 944-982
12. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006 ; 105: 198-208
13. Bennett-Guerrero E, Zhao Y, O'Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA. 2010 ; 304: 1568-1575
14. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004 ; 109: 2698-2704
15. Levy JH, Sniecinski RM. Prohemostatic treatment in cardiac surgery. Semin Thromb Hemost. 2012 ; 38: 237-243
16. Sniecinski RM, Levy JH. Bleeding and management of coagulopathy. J Thorac Cardiovasc Surg. 2011 ; 142: 662-667
17. Bolliger D, Görlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology. 2010 ; 113: 1205-1219
18. Esper SA, Levy JH, Waters JH, Welsby IJ. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg. 2014 ; 118: 731-743
19. Stahl GL, Shernan SK, Smith PK, Levy JH. Complement activation and cardiac surgery: a novel target for improving outcomes. Anesth Analg. 2012 ; 115: 759-771
20. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009 ; 108: 1433-1446
21. Holloway DS, Summaria L, Sandesara J, Vagher JP, Alexander JC, Caprini JA. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost. 1988 ; 59: 62-67
22. Rinder CS, Mathew JP, Rinder HM, Bonan J, Ault KA, Smith BR. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology. 1991 ; 75: 563-570
23. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology. 1991 ; 75: 388-393
24. Edmunds LH. Managing fibrinolysis without aprotinin. Ann Thorac Surg. 2010 ; 89: 324-331
25. Levi M, Fries D, Gombotz H, et al. Prevention and treatment of coagulopathy in patients receiving massive transfusions. Vox Sang. 2011 ; 101: 154-174
26. Görlinger K, Dirkmann D, Hanke AA. Potential value of transfusion protocols in cardiac surgery. Curr Opin Anaesthesiol. 2013 ; 26: 230-243
27. Sniecinski RM, Chandler WL. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg. 2011 ; 113: 1319-1333
28. Rozental T, Shore-Lesserson L. Pharmacologic management of coagulopathy in cardiac surgery: an update. J Cardiothorac Vasc Anesth. 2012 ; 26: 669-679
29. Karkouti K, McCluskey SA, Syed S, Pazaratz C, Poonawala H, Crowther MA. The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study. Anesth Analg. 2010 ; 110: 1533-1540
30. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg. 2012 ; 114: 261-274
31. Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion. 2008 ; 48: 2152-2158
32. Nielsen VG, Cohen BM, Cohen E. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand. 2005 ; 49: 222-231
33. Karkouti K, Callum J, Crowther MA, et al. The relationship between fibrinogen levels after cardiopulmonary bypass and large volume red cell transfusion in cardiac surgery: an observational study. Anesth Analg. 2013 ; 117: 14-22
34. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003 ; 75: S715 - S720
35. Esmon CT. The protein C pathway. Chest. 2003 ; 124: 26S - 32S
36. Esmon CT. Coagulation and inflammation. J Endotoxin Res. 2003 ; 9: 192-198
37. Ranucci M. The endothelial function in cardiac surgery. Minerva Anestesiol. 2006 ; 72: 503-506
38. Esmon CT. Inflammation and thrombosis. J Thromb Haemost. 2003 ; 1: 1343-1348
39. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999 ; 88: 312-319
40. Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. Guidelines on the management of massive blood loss. Br J Haematol. 2006 ; 135: 634-641
41. Steiner ME, Despotis GJ. Transfusion algorithms and how they apply to blood conservation: the high-risk cardiac surgical patient. Hematol Oncol Clin North Am. 2007 ; 21: 177-184
42. Ferraris VA, Ferraris SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007 ; 83: S27 - S86
43. Perry DJ, Fitzmaurice DA, Kitchen S, Mackie IJ, Mallett S. Point-of-care testing in haemostasis. Br J Haematol. 2010 ; 150: 501-514
44. Darcy MD, Kanterman RY, Kleinhoffer MA, et al. Evaluation of coagulation tests as predictors of angiographic bleeding complications. Radiology. 1996 ; 198: 741-744
45. Munro J, Booth A, Nicholl J. Routine preoperative testing: a systematic review of the evidence. Health Technol Assess. 1997 ; 1: 1-62
46. Manning SC, Beste D, McBride T, Goldberg A. An assessment of preoperative coagulation screening for tonsillectomy and adenoidectomy. Int J Pediatr Otorhinolaryngol. 1987 ; 13: 237-244
47. Houry S, Georgeac C, Hay JM, Fingerhut A, Boudet MJ. A prospective multicenter evaluation of preoperative hemostatic screening tests. The French Associations for Surgical Research. Am J Surg. 1995 ; 170: 19-23
48. Haas T, Spielmann N, Mauch J, et al. Comparison of thromboelastometry (ROTEM®) with standard plasmatic coagulation testing in paediatric surgery. Br J Anaesth. 2012 ; 108: 36-41
49. Haas T, Spielmann N, Mauch J, Speer O, Schmugge M, Weiss M. Reproducibility of thrombelastometry (ROTEM®): point-of-care versus hospital laboratory performance. Scand J Clin Lab Invest. 2012 ; 72: 313-317
50. Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth. 2004 ; 92: 178-186
51. Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth. 2001 ; 86: 575-578
52. Nuttall GA, Oliver WC, Santrach PJ, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology. 2001 ; 94: 773-781
53. Ak K, Isbir CS, Tetik S, et al. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg. 2009 ; 24: 404-410
54. Westbrook AJ, Olsen J, Bailey M, Bates J, Scully M, Salamonsen RF. Protocol based on thromboelastograph (TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: a pilot study. Heart Lung Circ. 2009 ; 18: 277-288
55. Weber CF, Görlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012 ; 117: 531-547
56. Görlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology. 2011 ; 115: 1179-1191
57. Hanke AA, Herold U, Dirkmann D, Tsagakis K, Jakob H, Görlinger K. Thromboelastometry based early goal-directed coagulation management reduces blood transfusion requirements, adverse events, and costs in acute type a aortic dissection: a pilot study. Transfus Med Hemother. 2012 ; 39: 121-128
58. Girdauskas E, Kempfert J, Kuntze T, et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg. 2010 ; 140: 1117.e2-1124.e2
59. Hertfelder HJ, Bos M, Weber D, Winkler K, Hanfland P, Preusse CJ. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin Thromb Hemost. 2005 ; 31: 426-440
60. Tanaka KA, Bolliger D, Vadlamudi R, Nimmo A. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth. 2012 ; 26: 1083-1093
61. Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol. 2014 ; 89: 228-232
62. Sniecinski RM, Karkouti K, Levy JH. Managing clotting: a North American perspective. Curr Opin Anaesthesiol. 2012 ; 25: 74-79
63. Maquelin KN, Berckmans RJ, Nieuwland R, et al. Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1998 ; 115: 1160-1165
64. Wenger RK, Lukasiewicz H, Mikuta BS, Niewiarowski S, Edmunds LH. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1989 ; 97: 235-239
65. Enriquez LJ, Shore-Lesserson L. Point-of-care coagulation testing and transfusion algorithms. Br J Anaesth. 2009 ; 103: i14 - i22
66. Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost. 2009 ; 35: 150-157
67. Weitzel NS, Weitzel LB, Epperson LE, Karimpour-Ford A, Tran ZV, Seres T. Platelet mapping as part of modified thromboelastography (TEG®) in patients undergoing cardiac surgery and cardiopulmonary bypass. Anaesthesia. 2012 ; 67: 1158-1165
68. Schimmer C, Hamouda K, Sommer SP, Ozkur M, Hain J, Leyh R. The predictive value of multiple electrode platelet aggregometry (multiplate) in adult cardiac surgery. Thorac Cardiovasc Surg. 2013 ; 61: 733-743
69. Orlov D, McCluskey SA, Selby R, Yip P, Pendergrast J, Karkouti K. Platelet dysfunction as measured by a point-of-care monitor is an independent predictor of high blood loss in cardiac surgery. Anesth Analg. 2014 ; 118: 257-263
70. Görlinger K, Fries D, Dirkmann D, Weber CF, Hanke AA, Schochl H. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. Transfus Med Hemother. 2012 ; 39: 104-113
71. Stanworth SJ, Grant-Casey J, Lowe D, et al. The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. Transfusion. 2011 ; 51: 62-70
72. Stanworth SJ, Walsh TS, Prescott RJ, et al. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. Crit Care. 2011 ; 15: R108
73. Welsby IJ, Troughton M, Phillips-Bute B, et al. The relationship of plasma transfusion from female and male donors with outcome after cardiac surgery. J Thorac Cardiovasc Surg. 2010 ; 140: 1353-1360
74. Bjursten H, Dardashti A, Ederoth P, Brondén B, Algotsson L. Increased long-term mortality with plasma transfusion after coronary artery bypass surgery. Intensive Care Med. 2013 ; 39: 437-444
75. Sarani B, Dunkman WJ, Dean L, Sonnad S, Rohrbach JI, Gracias VH. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Crit Care Med. 2008 ; 36: 1114-1118
76. Khan SA, Priyamvada S, Arivarasu NA, Khan S, Yusufi AN. Influence of green tea on enzymes of carbohydrate metabolism, antioxidant defense, and plasma membrane in rat tissues. Nutrition. 2007 ; 23: 687-695
77. Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation. 2009 ; 120: 21-27
78. Karkouti K, Beattie WS, Arellano R, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation. 2008 ; 118: 331-338
79. Tanaka KA, Esper S, Bolliger D. Perioperative factor concentrate therapy. Br J Anaesth. 2013 ; 111: i35 - i49
80. Görlinger K, Bergmann L, Dirkmann D. Coagulation management in patients undergoing mechanical circulatory support. Best Pract Res Clin Anaesthesiol. 2012 ; 26: 179-198
81. Weber CF, Klages M, Zacharowski K. Perioperative coagulation management during cardiac surgery. Curr Opin Anaesthesiol. 2013 ; 26: 60-64
82. Levy JH, Adkinson NF. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg. 2008 ; 106: 392-403
83. Gottschlich GM, Gravlee GP, Georgitis JW. Adverse reactions to protamine sulfate during cardiac surgery in diabetic and non-diabetic patients. Ann Allergy. 1988 ; 61: 277-281
84. Levy JH. Anaphylactic/anaphylactoid reactions during cardiac surgery. J Clin Anesth. 1989 ; 1: 426-430
85. Lowenstein E, Zapol WM. Protamine reactions, explosive mediator release, and pulmonary vasoconstriction. Anesthesiology. 1990 ; 73: 373-375
86. Dykewicz MS, Kim HW, Orfan N, Yoo TJ, Lieberman P. Immunologic analysis of anaphylaxis to protamine component in neutral protamine Hagedorn human insulin. J Allergy Clin Immunol. 1994 ; 93: 117-125
87. Cormack JG, Levy JH. Adverse reactions to protamine. Coron Artery Dis. 1993 ; 4: 420-425
88. Kimmel SE, Sekeres MA, Berlin JA, Ellison N, DiSesa VJ, Strom BL. Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. J Am Coll Cardiol. 1998 ; 32: 1916-1922
89. Kimmel SE, Sekeres MA, Berlin JA, Goldberg LR, Strom BL. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. J Clin Epidemiol. 1998 ; 51: 1-10
90. Samuel T. Antibodies reacting with salmon and human protamines in sera from infertile men and from vasectomized men and monkeys. Clin Exp Immunol. 1977 ; 30: 181-187
91. Weiler JM, Gellhaus MA, Carter JG, et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol. 1990 ; 85: 713-719
92. Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998 ; 87: 781-785
93. Mittermayr M, Velik-Salchner C, Stalzer B, et al. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study. Anesth Analg. 2009 ; 108: 743-750
94. Cattaneo M, Harris AS, Stromberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery - a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost. 1995 ; 74: 1064-1070
95. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007 ; 356: 2301-2311
96. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007 ; 297: 471-479
97. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006 ; 354: 353-365
98. Shaw AD, Stafford-Smith M, White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med. 2008 ; 358: 784-793
99. Skyring A, Singer A, Tornya P. Treatment of acute pancreatitis with trasylol: report of a controlled therapeutic trial. BMJ. 1965 ; 2: 627-629
100. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999 ; 354: 1940-1947
101. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004 ; 128: 442-448
102. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008 ; 358: 2319-2331
103. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg. 2010 ; 110: 21-29
104. Horrow JC, Abrams JT, Van Riper DF, Lambson DL, Storella RJ. Ventilatory compliance after three sufentanil-pancuronium induction sequences. Anesthesiology. 1991 ; 75: 969-974
105. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg. 1994 ; 58: 1580-1588
106. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011 ; (3). CD001886
107. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg. 1997 ; 85: 1258-1267
108. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg. 2008 ; 107: 1783-1790
109. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg. 2010 ; 110: 350-353
110. Lecker I, Wang DS, Romaschin AD, Peterson M, Mazer CD, Orser BA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest. 2012 ; 122: 4654-4666
111. Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost. 2005 ; 93: 1101-1107
112. Ternstrom L, Radulovic V, Karlsson M, et al. Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study. Thromb Res. 2010 ; 126: e128 - e133
113. Rahe-Meyer N, Pichlmaier M, Haverich A, et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth. 2009 ; 102: 785-792
114. Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology. 2013 ; 118: 40-50
115. Lee SH, Lee SM, Kim CS, et al. Use of fibrin-based thromboelastometry for cryoprecipitate transfusion in cardiac surgery involving deep hypothermic circulatory arrest during cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2010 ; 21: 687-691
116. Rahe-Meyer N, Solomon C, Tokuno ML, et al. Comparative assessment of coagulation changes induced by two different types of heart-lung machine. Artif Organs. 2010 ; 34: 3-12
117. Pipe SW. Recombinant clotting factors. Thromb Haemost. 2008 ; 99: 840-850
118. Godje O, Haushofer M, Lamm P, Reichart B. The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg. 1998 ; 46: 263-267
119. Shainoff JR, Estafanous FG, Yared JP, DiBello PM, Kottke-Marchant K, Loop FD. Low factor XIIIA levels are associated with increased blood loss after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1994 ; 108: 437-445
120. Godje O, Gallmeier U, Schelian M, Grunewald M, Mair H. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg. 2006 ; 54: 26-33
121. Karkouti K, von Heymann C, Jespersen CM, et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg. 2013 ; 146: 927-939
122. Steiner ME, Key NS, Levy JH. Activated recombinant factor VII in cardiac surgery. Curr Opin Anaesthesiol. 2005 ; 18: 89-92
123. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005 ; 95: 596-602
124. von Heymann C, Redlich U, Jain U, et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery - a retrospective analysis of safety and efficacy. Crit Care Med. 2005 ; 33: 2241-2246
125. Warren O, Mandal K, Hadjianastassiou V, et al. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg. 2007 ; 83: 707-714
126. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010 ; 363: 1791-1800
127. Tanaka KA, Taketomi T, Szlam F, Calatzis A, Levy JH. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg. 2008 ; 106: 732-738
128. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007 ; 370: 439-448
129. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost. 2012 ; 10: 1478-1485
130. Wojcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med. 2009 ; 2: 217-225
131. Bolliger D, Sreeram G, Duncan A, et al. Prophylactic use of factor IX concentrate in a Jehovah's Witness patient. Ann Thorac Surg. 2009 ; 88: 1666-1668
132. Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013 ; 128: 1234-1243
133. Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010 ; 99: 251-260
134. Arnekian V, Camous J, Fattal S, Rezaiguia-Delclaux S, Nottin R, Stephan F. Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact Cardiovasc Thorac Surg. 2012 ; 15: 382-389
135. Hanke AA, Joch C, Görlinger K. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. Br J Anaesth. 2013 ; 110: 764-772
136. Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008 ; 12: R105
137. Schick KS, Fertmann JM, Jauch KW, Hoffmann JN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care. 2009 ; 13: R191
138. Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011 ; 106: 429-438
139. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth. 1995 ; 9: 168-173
140. Spalding GJ, Hartrumpf M, Sierig T, Oesberg N, Kirschke CG, Albes JM. Cost reduction of perioperative coagulation management in cardiac surgery: value of "bedside" thrombelastography (ROTEM). Eur J Cardiothorac Surg. 2007 ; 31: 1052-1057